A narrow majority of shareholders of Transkaryotic Therapies has approved the biotechnology firm's $1.6 billion sale to a British drug company. The takeover by Shire Pharmaceuticals had been opposed by Transkaryotics' former CEO, who quit in protest. Key investors had also argued the price that Shire is paying is too low. Dissident shareholders, including investor Carl Icahn, are expected to continue fighting the deal in court.
- read this story from the Boston Herald for more